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Skin toxicity is associated with a number of different chemotherapeutic 
agents used to treat acute leukemias, including cytarabine, 
daunorubicin, doxorubicin, and methotrexate. While alopecia and 
radiation recall are well-recognized cutaneous side effects, more 
recently the term “toxic erythema of chemotherapy” (TEC) has been 
coined to describe a spectrum of skin findings, ranging from palmar-
plantar erythrodysesthesia to erythema of major body folds, with 
erythroderma representing its most severe form. In this retrospective 
study of 49 patients with acute leukemia, 10 patients were treated 
with clofarabine alone (40 mg/m2 daily for 5 days) and 40 patients 
received this dose of clofarabine plus cytarabine (1 g/m2 daily for 5 
days); one patient received each of the two regimens with an interval 
of 6 weeks between administrations. Treatment-associated skin 
toxicity, including TEC, developed 3 to 9 days following the initiation of 
chemotherapy and was more common in the group receiving the two-
drug combination as compared to those receiving clofarabine alone 
(22/40 [55%] versus 1/10 [10%] respectively; p=0.014). The 
majority of chemotherapy-related cutaneous side effects represented 
TEC. Clinicians should be aware of the potential for additive or 
synergistic skin toxicity in the setting of the combination of clofarabine 
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a. Overview of mucocutaneous toxicity of chemotherapy agents 
  
Chemotherapy is an important treatment modality for 
multidisciplinary cancer management. Cancer is the second leading 
cause of death only after heart disease. According to the American 
Cancer Society, in 2013, there were estimated 1.7 million new cancer 
cases and 580,350 deaths due to cancer, which represents 
approximately 1,600 deaths per day or one in every four deaths.(1) 
 
Various types of mucocutaneous reactions commonly occur in 
patients undergoing chemotherapy, including drug hypersensitivities, 
skin changes due to graft versus host disease (GVHD) and infections in 
neutropenic patients. Therefore correct attribution of the cause of the 
skin reactions is important for appropriate patient management. 
Understanding the potential risk associated with a given chemotherapy 
agent facilitates the distinction of the most likely offending drug 
causing a mucocutaneous reaction from a variety of other medications 
that are being concomitantly administered. It also facilitates 
appropriate counseling of patients about potential side effects of the 
chemotherapy agents that are to be administered. Mucocutaneous 
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reactions are frequent and visible, thus recognizing them early and 
starting proper prophylaxis or treatment play an important role in 
cancer patients’ psychological health and quality of life.  
 
More than fifty mucocutaneous toxicities have been described in 
the literature with over thirty chemotherapy agents.(2, 3). Herein 
described are the most common types of mucocutaneous toxicities 
associated with chemotherapeutic agents, including a spectrum of 
overlapping painful erythemas collectively called toxic erythema of 
chemotherapy (TEC).(4) 
 
Acneiform eruptions  
 
Acneiform eruptions, or papulopustular eruptions, are 
characterized by sterile pustules and erythematous papules. They are 
commonly distributed in the seborrheic areas, including the scalp, face, 
neck, central chest, upper back, and behind the ears; palms and soles 
are spared.(5, 6)  Most frequently reported with the use of epidermal 
growth factor receptor (EGFR) inhibitors, acneiform eruptions are 
generally self-limited and dose-dependent. The acne-like rash has 
been reported as a side effect with increased frequency in patients 
treated with gefitinib, erlotinib and cetuximab.(7-9) Interestingly, a 
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number of studies have suggested that the severity of acneiform 
eruption is positively associated with the tumor response to EGFR 
inhibitors and overall survival.(10-12) However, prospective studies 
are needed to examine the association between dermatologic eruption 
and tumor response.  
 
The widespread pustules of acneiform eruptions could look alike 
with bacterial infections, steroid acne, or disseminated herpes zoster. 
Therefore appropriate tests such as culture of the pustules to rule out 
any infections are necessary to confirm the diagnosis of acneiform 
eruptions.(13) Tetracyclines have been shown to have efficacy in 
acneiform eruption prophylaxis in cetuximab therapy.(14) There is no 
standard therapy for acneiform eruptions. Several strategies that have 
been described include tetracyclines, metronidazole, clindamycin gel, 




Anagen, catagen and telogen complete the three phases of hair 
growth. A number of chemotherapeutic agents induce hair loss 
(alopecia) by one of two mechanisms:  anagen effluvium and telogen 
effluvium. Anagen is the active phase of hair growth; anagen 
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elffluvium is defined as the pathologic loss of the anagen phase of hair, 
which typically occurs within two to three weeks of the administration 
of chemotherapeutic agents. Telogen is the follicular resting phase of 
hair growth, telogen effluvium occurs later, about two to four months 
after drug administration.(17) Alopecia can be caused by most 
chemotherapeutic agents; including taxanes, etoposide, bleomycin, 
dactinomycin, cytarabine and vinca alkaloids.(18, 19) However, 
liposomal anthracyclines and gemcitabine rarely induce alopecia.(19, 
20) On the other hand, trichomegaly and abnormal hair growth have 
also been reported with the use EFGR inhibitors.(21-23) 
 
In most cases, abnormal hair growth and alopecia resolve 
spontaneously after cessation of the offending drugs. A few treatment 
strategies have been explored to prevent or delay the onset of 
alopecia in human and animal models. Application of a scalp tourniquet 
and various drugs such as minoxidil have shown limited success.(24, 
25) In a recent prospective randomized trial, scalp cooling reduced risk 
of alopecia occurrence by 78% in patients treated with docetaxel.(26)  
 




Erythema multiforme (EM) is an acute, immune-mediated 
mucocutaneous reaction caused by medications and certain infections, 
most commonly herpes simplex virus. EM lesions are characterized by 
targetoid erythematous plaques with central color variations.(27) 
These lesions are usually on acral surfaces, however mucosal 
involvement can occur in up to 60% of the cases.(28) Stevens-
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum 
of mucocutaenous lesions distinct from EM. The lesions in SJS/TEN are 
typically erythematous or pruritic macules that are more predominant 
on the face and trunk as apposed to the acral distribution in EM.(27) 
Mucous membranes are involved in almost all cases. The difference 
between SJS and TEN is the degree of the involvement by epidermal 
detachment; with SJS involving less than 10%, and TEN involving 
more than 30% of the total body surface area. If the epidermal 
detachment involves 10%-30% of the body surface area, it is denoted 
as the SJS/TEN overlapping syndrome.  Recent studies have shown 
that certain human leukocyte antigens (HLA) alleles are associated 
with the activation of cytotoxic T cells that initiate SJS/TEN.(29) 
Therefore different drug antigens and the genetic make-up of the 




Several chemotherapy agents have been implicated in EM, such 
as docetaxel and flurouracil.(32, 33) Other than removing offending 
drugs, there are no controlled studies demonstrating efficacy of 
systemic corticosteroids treatment for drug-induced EM. However, 
symptom management such as with antiseptic/antihistamine rinses 
and local anesthetic solutions are beneficial.(34) SJS/TEN has been 
observed with concurrent gemcitabine and radiation therapy, as well 
as with rituximab and as localized epidermal necrolysis of the skin over 
vinblastine infusion site.(35-37) The management of SJS/TEN entails 
meticulous supportive care similar to that for burn patients, including 
antiseptics to minimize infection and sepsis risk, electrolytes and fluid 
repletion, wound care, and eye ointment. The use of systemic 
corticosteroids and IVIG remains uncertain as there is no prospective 




Hypersensitivity reactions to chemotherapeutic agents are 
immune-mediated allergic reactions. There are four types of 
hypersensitivity reactions, as defined by Gell and Coombs.  Type I 
hypersensitivity is IgE antibody mediated response; Type II is IgG or 
IgM mediated cytotoxic response; Type III is immune-complex 
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mediated response; and Type IV is delayed, cell-mediated 
response.(40) Type I responses are immediate reactions, sometimes 
called anaphylactic hypersensitivities; its symptoms can range from 
minor pruritus, flushing, wheals formation on the skin and mucous 
secretion, to hypotension, angioedema, and death. Anaphylactic 
reactions have been reported with paclitaxel and platinum based 
agents such as carboplatin.(3) In the case of paclitaxel, prophylactic 
premedication with anti-histamines and corticosteroids before drug 
infusion is now routinely used, however hypersensitivity may still occur 
in 2-5% of patients.(41) For carboplatin, antihistamines may be 
helpful for mild cases, but premedication with corticosteroids and 
antihistamines are not sufficient for more severe reactions involving 
the respiratory system, in which case, the discontinuation of the drug, 
or switch to a different platinum-based medication are 
recommended.(42, 43) 
 
Type II hypersensitivity includes immune thrombocytopenia, 
neutropenia, and hemolytic anemia; and type III responses typically 
can manifest as vasculitis and serum sickness syndrome. Many 
monoclonal antibodies such as rituximab, alemtuzumab, alemtuzumab, 
and bevacizumab are thought to cause type II and type III 
hypersensitivity reactions. For example, rituximab has been reported 
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to cause immune mediated thrombocytopenia, neutropenia, hemolytic 
anemia, as well as allergic vasculitis and serum sickness-like 
reactions.(44-47) Type IV hypersensitivity are delayed reactions that 
generally develop hours to days after exposure. Examples of drug-
induced type IV reactions include drug reaction with eosinophilia and 
systemic symptoms (DRESS), fixed drug eruptions, SJS, TEN, and 
EM.(48) They are characterized by pruritic, erythematous papules 
and/or plaques, or a morbilliform drug eruption. Cladribine associated 
hypersensitivity, which causes cutaneous reactions and peripheral 
eosinophilia, is thought to be a delayed hypersensitivity (type IV).(49) 
A bullous fixed drug eruption has been associated with paclitaxel. It is 
clinically characterized by bullae formation over dusky erythematous 
patches and development of ulcers after bullae rupture. It tends to 
occur within the first two days after paclitaxel infusion and re-exposure 
of paclitaxel will cause bullous response to recur within the same 
anatomical region.(50) There are no treatment guidelines for 
chemotherapy-induced hypersensitivity. Desensitization and 
premedication with steroids and antihistamines may be helpful, 





Hyperpigmentation is another common manifestation of 
cutaneous toxicity due to chemotherapy. For example, Fluorouracil 
administration may cause patchy, reticulate and mottled 
hyperpigmentation.(51) Cyclophosphamide can cause diffuse 
hyperpigmentation of the mucosa, teeth, tongue, nails, palms and 
soles, with nail pigmentation being the most common.(52, 53) A 
recent case report describes a patient who developed generalized 
reticulated pigmentation on the face, trunk and extremities after 
receiving cyclophosphamide, which cleared gradually in the next seven 
months, but the pigmentation aggravated when cyclophosphamide 
was resumed. The histology of skin biopsy showed “hyperplasia, 
parakeratosis and multiple necrotic keratinocytes in the epidermis”.(52) 
Brownish pigmentation of the nails is commonly seen with 
hydroxyurea. In addition, it has been reported that hydroxyurea can 
cause blue discoloration of the lunula.(54) The exact mechanism of the 
nail pigmentation is not clear, but it may be caused by focal 
stimulation of melanocytes leading to deposition of melanin in the nail 
matrix or a direct toxic effect on the distal nail matrix basal cells.(55) 
Weekly intravenous infusion of docetaxel has been reported to cause a 
supravenous red skin pigmentation above the infusion site, without 
evidence of infiltration of the veins or phlebitis.(56) Although docetaxel 
may increase the permeability of the vascular endothelium and lead to 
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edema, the mechanism of this discoloration is not clear.(57) 
Anthracyclines such as daunorubicin occasionally cause skin 
hyperpigmentation in both sun-exposed and sun-protected areas. The 
proposed mechanism is damage and subsequently repair of 
melanocytes by intercalation of anthracyclines resulting in 
hyperpigmentation of the skin.(58) Recently a case of palatal 
melanosis was reported in a patient receiving Imatinib for chronic 
myelogenous leukemia, which adds to the previously known side 
effects of hypopigmentation or hyperpigmentation in imatinib.(59) The 
proposed mechanism of imatinib-induced hypo- or hyper-pigmentation 
is that the receptor tyrosine kinase c-Kit plays important regulatory 
roles in melanogenesis, pigmentation and melanocyte homeostasis.(60) 
 
Chemotherapy induced hyperpigmentation generally resolves 
over months to years.(51) Topical retinoids may be beneficial to 
stimulate rapid turnover of keratinocytes with subsequent loss of 
melanin. Topical products containing hydroquinone and corticosteroids 
may also decrease melanin synthesis. Avoidance of sun exposure and 





Xerosis, or dry skin, can occur with several chemotherapy agents, 
appearing several weeks after treatment in up to 35% of patients in 
clinical trials.(10) Patients often complain of dry skin, pain and 
itchiness. Left unattended, xerosis can evolve into asteatotic eczema, 
which can lead to secondary Staphylococcus aureus or Herpes simplex 
infections.(61) It is a common side effect with administration of 
epidermal growth factor receptor (EGFR) inhibitors such as cetuximab. 
EGFR inhibition causes keratinocyte growth arrest and initiate terminal 
differentiation of basal keratinocytes in vitro, which could explain the 
clinical presentation of fine scaling in xerosis. Histologic changes are 
subtle in the epidermis, with loss of the basket-weave appearance in 
the thin stratum corneum, and compact on with parakeratosis.(62) In 
addition to diffuse dry skin, several patients treated with Gefitinib 
reported vaginal dryness and itching, perineal dryness, and eye 
irritations including blepharitis.(63)  
 
Preventative measures for xerosis include frequent use of 
moisturizing emollients, avoiding soap, and application of short 
showers with decreased water temperature. Xerosis and desquamation 
can be treated with emollients such as petroleum jelly and Aquaphor®, 
or standard emollients such as 5-10% urea in cetomacrogol cream.(64) 
Topical corticosteroids can be used intermittently to treat eczema, 
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Many other skin toxicities have been associated with various 
chemotherapeutic agents. Autoimmune phenomena such as 
scleroderma and Raynaud’s phenomenon have been associated with 
the use of bleomycin.(65) Lupus erythematosus and dermatomyositis-
like eruptions are found with hydroxyurea administration.(66) 
Hydroxyurea also induces nail changes including brittle nails, 
longitudinal or transverse bands, and brownish pigmentation.(54) The 
incidence of extravasation from systemic chemotherapy infusion has 
been decreasing with the awareness and use of central catheters and 
ports. However, tissue necrosis from anthracycline extravasation 
happens slowly and can be missed, with catastrophic 
consequences.(67) A tissue recall phenomenon can occur with various 
agents including adriamycin, docetaxel, and epirubicin, where tissue 
necrosis happens at a site of prior tissue damage even if the 
chemotherapeutic agent is administered through different 
extremities.(68) Mucositis is another common side effect associated 
with several agents including methotrexate, cytarabine and 
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fluorouracil.(69) Mucositis is typically dose-dependent, and it can be 
life threating in the case of gastrointestinal mucosal damage.(70)  
 




Toxic erythema of chemotherapy (TEC) is a clinicopathological 
term suggested by Bolognia and others to unify a group of overlapping 
toxic skin reactions following chemotherapy.(4) The cutaneous findings 
range from painful palmar-plantar erythrodysesthesia (hand-foot 
syndrome) to dusky erythema of the major body folds. These lesions 
are characterized by painful and often edematous erythema most 
commonly involving hands and feet, intertriginous areas such as axilla 
and groin, and less often, the elbows, knees, neck, and ears.(4) 
(Figure 1) Previously, multiple clinical and histological names have 
been used to describe these skin eruptions. For example, terms 
including “hand-foot syndrome”, “palmar-plantar erythema”, “palmar-
plantar erythrodysesthesia” and “acral erythema” have all been used 
to describe the cutaneous toxic effects of chemotherapy manifested on 
hands and feet.(71-74) However, the same appearance of the 
erythematous patches that develop edema, desquamation, bullae, or 
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purpura, can also be found in other areas of the body.  “Ara-C ears” is 
one example that describes painful erythema and swelling of the ears 
after cytarabine administration.(75) Therefore a simplified term to 
describe the spectrum of these localized erythematous eruptions can 
avoid confusion and rule out differential diagnoses such as infection, 
allergy, or graft-versus-host-disease (GVHD). The onset of localized 
TEC is usually between 2 days to 3 weeks following the chemotherapy 
administration. There is associated pain, burning, pruritus, and 
paresthesia sensation on the skin lesions. Typically desquamation and 
spontaneous resolution of the skin lesions happen without specific 
therapy.(76, 77) 
 
A more generalized form of TEC is erythroderma, defined as 
generalized erythema and scaling involving more than 90% of the skin 
surface. The term is not a discrete entity, but rather a presentation of 
underlying causes such as atopic dermatitis, psoriasis, cutaneous T cell 
lymphoma (CTCL) or drug reactions.(78) In the context of 
chemotherapeutic agents, development of erythroderma can be 
viewed as a generalized, and sometimes more severe, form of TEC. 
The clinical features of erythroderma include pruritus, scaling, bullae 
formation, and intense pruritus resulting in scratch induced 
lichenification.(78) Extensive erythroderma resembles severe sunburn, 
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including being followed by desquamation, but without sparing of non-
sun-exposed sites. See figure 2 for a schematic summary of the 
spectrum of toxic erythema of chemotherapy. 
 
Diagnosis and treatment 
 
The prompt recognition and diagnosis of TEC is important 
because the alternative differential diagnoses such as infections, GVHD, 
or allergic reactions require immediate management plans. Staggering 
numbers of chemotherapeutic agents can cause TEC. The most 
common drugs associated with localized TEC are cytarabine, 
anthracyclines, 5-fluorouracil, capecitabine, taxanes and 
methotrexate.(4) Histologically, local TEC, such as palmar-plantar 
erythrodysesthesia, lacks specific findings. Scattered necrotic and 
dyskeratotic keratinocytes, basal layer vacuolar degeneration, dermal 
edema, and eccrine squamous syringometaplasi and/or eccrine 
hidradenitis are frequently described.(77, 79)  
 
There is no specific standard treatment for TEC. The main 
management strategy for TEC is symptomatic support to lessen pain, 
edema, and to prevent super-infection. Most localized TEC lesions 
resolve within a month after dose modification or cessation of the 
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causative agent(s). Other therapies described in small series have 
showed some efficacy, however large trials are lacking. Ice packs 
applied around wrists and ankles in patients treated with liposomal 
doxorubicin have led to reduced incidence of palmar-plantar 
erythrodysesthesia.(80) Oral dexamethasone has also been shown to 
alleviate localized TEC in patients undergoing liposomal doxorubicin 
treatment.(81) Other treatments suggested in case reports and 
retrospective studies include topical DMSO and COX2 inhibitors.(82, 83) 
A recent single-institution phase III trial showed celecoxib reduced 
incidence of hand-foot syndrome in patients treated with 
capecitabine.(84) Though some literature suggests that oral pyridoxine 
might provide benefit for the prevention or treatment of palmar-
plantar erythrodysesthesia, strong evidence of any proving treatment 
is lacking.(85) Two double-blinded randomized trials recently did not 
show prevention of hand-foot syndrome in patients received oral 
pyridoxine versus placebo.(86, 87) Dose modification or treatment 
cessation remains the main strategy if TEC develops.(82, 83) 
 
The chemotherapeutic agents most frequently associated with 
erythroderma are bevacizumab, imatinib, isotretinoin and 
thalidomide.(88) The diagnosis of erythroderma can be made based on 
its clinical presentation of erythema and scaling involving more than 
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90% of the total body surface area. The histologic features of drug-
induced erythroderma are often nonspecific, with necrotic 
keratinocytes, vacuolar changes and inflammatory infiltrates.(89) 
Supportive treatment for erythroderma includes maintaining fluid and 
electrolyte balance, preventing secondary infections and 
symptomatically managing inflammation and pruritus. In erythroderma 
with bullae formation, placing windows in the most dependent portions 
of bullae in order to allow drainage of initially sterile fluid while 
preserving the blister roof as a “natural bandage” is helpful. Topical 
and systemic corticosteroids may be beneficial, but no prospective 
trials have been done to suggest their efficacy.(90-92) ICU level care 
may be required for extensive erythroderma. Dose modification and 
drug cessation remain necessary if severe clinical symptoms develop. 
 
 
c. Overview of cytarabine, clofarabine, and their skin toxicities 
 
Clofarabine and cytarabine 
 
Nucleoside analogs have been a class of highly effective agents 
in the treatment of leukemias, lymphomas and other hematologic 
disorders. Examples of nucleoside analogs include gemcitabine, 
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azacitidine, cladribine, cytarabine, and recently, clofarabine.(93-97)  
 
Cytarabine, or cytosine arabinoside (Ara-C), is one of the most 
active chemotherapeutic agents used in the treatment of leukemias 
and other hematologic malignancies. It is a synthetic analog of 
nucleoside cytidine and it differs from cytidine by an additional β -
hydroxyl group in the 2’ position of the sugar moiety.(98) Cytarabine 
is metabolized in the liver to its active form aracytidine triphosphate 
by deoxycytidine kinase and other nucleotide kinases, and is 
eventually rapidly deaminated to the non-cytotoxic metabolite uracil 
arabinoside (araU) by deoxycytidine deaminase.(99) Only 5-10% of 
cytarabine is excreted unchanged through the kidneys.(98) 
 
In 1965, the antineoplastic properties of cytarabine were 
demonstrated in animal models.(100) Three years later, it was 
introduced as a treatment for acute leukemia.(101) Cytarabine, in 
combination with an anthracycline, usually daunorubicin, has served as 
the standard induction therapy  (“7+3”) for acute myeloid leukemia 
(AML)for several decades. It is also used off-label in AML consolidation 
and salvage therapy, as well as in acute lymphoblastic leukemia (ALL), 
chronic myeloid leukemia (CML) and lymphomas.(102-106) 
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Clofarabine, molecular structure (2-chloro-2’-fluoro-deoxy-9-β-
D-arabinofuranosyladenine), is a second-generation nucleoside analog 
that combined the most favorable pharmacokinetic characteristics of 
cladribine and fludarabine with the goal of improving drug efficacy and 
minimize extramedullary toxicities of the other deoxynucleoside 
analogues.(107) Clofarabine moves into cells via active nucleoside 
transport as well as passive transport. In the cell, cellular kinases such 
as deoxycytidine kinase phosphorylate clofarabine to its active 
triphosphate form. Due to its higher resistance to phosphorolysis and 
deamination, clofarabine has greater stability and increased 
triphosphate retention.(108, 109) 
 
Clofarabine is approved in the United States for the treatment of 
relapsed or refractory ALL in pediatric population less than 21 years 
old who had at least two prior treatment regimens.(110) It is also for 
unlabeled use in refractory ALL and AML as a mono-therapy or 
combination therapy with cytarabine.(111-113) The 2013 National 
Comprehensive Cancer Network (NCCN) guidelines indicated that 
clofarabine could be used as frontline treatment of acute myelocytic 
leukemia (AML) in adults older than 60 years.(114)  
 
The rationale for combining clofarabine with cytarabine is based 
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on in-vitro studies showing that when cytarabine is administered after 
clofarabine, the conversion of cytarabine to its active triphosphate 
form is increased.(108) Faderl et al. have studied clofarabine and 
cytarabine combination as an induction therapy for AML in elderly 
patients. In one of their studies, cytarabine was given at 1g/m2/d from 
day 1 to day 5 and Clofarabine was given at 40mg/m2 from day 2 to 
day 6. Cytarabine was administrated four hours after clofarabine. The 
overall response rate was 60%.(115) They subsequently performed a 
randomized study of clofarabine versus clofarabine plus low-dose 
cytarabine as the front line therapy for patients 60 years and older 
with AML and high-risk myelodysplastic syndrome, which showed 
better event-free-survival (EFS) and complete response (CR) rate with 
the combination regimen but not overall survival.(112) In a recent 
phase III trial CLASSIC I (Clofarabine and Ara-C Studying Survival Via 
Induction and Consolidation), Faderl et al compared the combination of 
clofarabine plus cytarabine with cytarabine alone in older patients with 
refractory AML, and found better EFS and RR with the combination 
arm, however there was no OS difference between the arms.(111) 
Another recent phase II trial studied clofarabine in combination with 
cytarabine and idarubicin (CIA) as the induction therapy for patients 
age less than 60 with newly diagnosed AML. The overall response (OR) 
rate in the study was 79%, and longer overall survival (OS) and EFS 
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compared to historical patients treated with the cytarabine plus 
idarubicin regimen.(116) 
 
Cutaneous toxicity  
 
Cutaneous toxicities including TEC are known side effects of 
cytarabine. The mechanisms of the skin toxicity are not entirely clear. 
One plausible explanation is the toxicity to the epidermis and the 
eccrine ducts and glands, which are most concentrated in the skin of 
palms and feet.(117, 118) The incidence of TEC appears to be dose-
related. In a prospective study of skin reactions with high dose 
cytarabine, rashes occurred in 41% and 73% of patients who received 
a total dose of 24g/m2 and 30g/m2 of cytarabine respectively; of 
which morbilliform eruptions and acral erythema were most 
common.(18) High dose cytarabine is also associated with cytarabine 
syndrome, a rare immune-allergic reaction characterized by fever, 
bone and chest pain, conjunctivitis, rash, malaise and myalgia.(18)  
 
The package insert of clofarabine reports a 38% incidence of 
rash, a 13% incidence of erythema, and an 18% incidence of palmar-
plantar erythrodysesthesia. In one phase II study with clofarabine 
40mg/m2/day for 5 days, skin rashes and palmar-plantar 
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erythrodysesthesia were noted in 66% of patients.(119) There are 
potential synergistic effects of skin toxicities due to clofarabine and 
cytarabine combination therapy. In the Phase II trial of clofarabine 
(40mg/m2/day x 5 days) and cytarabine (1g/m2/day x 5 days) 
combination therapy by Faderl et al, skin rash was reported in 12 
patients (60%), of whom 9 of developed hand-foot syndrome (45%), 
which was severe (grade III or IV) in 3 patients (15%).(120) In the 
subsequent phase III study of the same combination regimen versus 
cytarabine plus placebo，15% of patients in the combination arm and 
6% of patients in the cytarabine plus placebo arm developed grade 3 
to 4 skin and subcutaneous toxicities. Palmar-plantar 
erythrodysesthesia occurred in 20% of patients in the combination arm 
and only 1% in the cytarabine plus placebo arm.(111) In two other 
studies, the combination therapies were associated with skin toxicities 
ranging from 40 to 82%.(112, 115) In a recent case report, a patient 
developed extensive TEC involving trunks, leg, feet and hands after 
receiving the combination therapy with clofarabine (40mg/m2/day x 5 
days) and cytarabine (1g/m2/day x 5 days). The skin lesions 
deteriorated and developed blisters, and the patient subsequently 




Statement of purpose and hypothesis  
 
This study aims to characterize the range of skin toxicities 
associated with clofarabine as well as clofarabine and cytarabine 
combination therapy in treatment of acute leukemias at Yale Cancer 
Center. We hypothesize that there will be additive or synergistic 
effects of the skin toxicities due to clofarabine and cytarabine 
combination therapy. 
 
Our secondary purpose is to emphasize the clinical importance of 
TEC and to increase the awareness of its high incidence in combination 





Institutional review board approval was obtained prior to this 
retrospective review of medical records of all adult patients with AML 
or ALL treated with clofarabine, either alone or in combination with 
cytarabine, at Yale-New Haven Hospital from December 2006 through 
February 2011. In order to facilitate comparison of the cutaneous 
toxicity observed following administration of clofarabine versus 
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clofarabine plus cytarabine, only patients who were treated with 
clofarabine 40 mg/m2 daily for 5 days [days 1 to 5] +/- cytarabine (1 
g/m2 daily for 5 days [days 2 to 6]) were included in this analysis. In 
addition to demographic and chemotherapy regimen data, available 
records of patients during and after the treatment period were 
reviewed in detail, including their hospital course, any complications, 
presence of cutaneous reactions, the description and progression of 
skin toxicity findings. Clinical criteria and, when available, dermatology 
consultations and skin biopsy results were used to distinguish TEC 
from other entities such as morbilliform drug reactions and infectious 
cellulitis. The severity of skin toxicity was graded according to 
Common Terminology Criteria for Adverse Events (CTCAE) Version 
4.0.(122) (See appendix 1 for a definition of each skin toxicity grade). 
CTCAE, published by National Cancer Institute, is a widely accepted 
grading scale in oncology research community as the standard grading 
system for adverse events. Its version 4.0 was published in May 2009. 
Descriptive statistical analysis, contingency table, and Fischer’s exact 
test were used to analyze the data. 
 
Bingnan Zhang collected the data and conducted the literature 
review for this project. Katherine Mandock extracted the pharmacy 
data for the patients studied. Bingnan Zhang, Peter Marks, Jean 
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Bolognia, and Nikolai Podoltsev contributed to the analysis and writing 






Table 1 shows the demographics and diagnoses of the 10 
patients treated with clofarabine alone and the 40 patients treated 
with a combination of clofarabine plus cytarabine. Note that one 
patient received both of these regimens, but the latter were separated 
by a sufficiently long time interval (6 weeks) such that the two courses 
were considered separate exposures. The mean age at time of 
treatment was 47 years, ranging between 20 to 77 years. About three 
quarters of the patients had acute myeloid leukemia, and the rest had 
acute lymphoid leukemia.  All of the patients had relapsed or primary 
refractory disease, and approximately 40% of the patients had 
previously undergone an allogeneic hematopoietic stem cell transplant. 
 
Table 2 outlines the types of cutaneous reactions seen in the 
patients in this series. The former are subdivided into those related to 
clofarabine and/or cytarabine and those that were due to other 
medications, fever, or the underlying hematologic malignancy. 
Twenty-two of 40 patients who received clofarabine plus cytarabine 
developed chemotherapy-related skin reactions, the majority of which 
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were toxic in nature rather than allergic. Of the four patients who 
developed erythroderma, three were assessed as grade 3 and one as 
grade 5 (Figure 3)(122). The medical records notes for the patient 
with grade 5 erythroderma recorded, on day two of clofarabine plus 
cytarabine treatment, the patient developed “whole body rash”, on day 
five of the treatment, “erythematous rash involving his trunk and 
extremities, which was thought secondary to clofarabine and 
cytarabine”, day six, “blistering developed in bilateral leg, large bullae 
developed below knees ranging in size from 0.5cm to 15cm diameter, 
dermatology suspected toxic erythema of chemotherapy, further 
developing into epidermal necrolysis. Day seven, patient admitted into 
ICU for “sepsis and hypoxic respiratory failure, significant leg 
tenderness with diffuse bullae over his feet and lower extremities”, 
and the patient deceased shortly after. A typical description of palmar-
plantar erythrodysesthesia in the medical chart is as follows: On day 4 
after chemotherapy treatment started, patient developed “pain and 
burning in bilateral hands and feet, oral pyridoxine was started”; on 
day 5, “hands and feet become edematous and erythematous, painful”; 
day 8, “hands and feet remain diffusely erythematous and swollen, 
skin is dry and beginning to peel, less pain”, day 13, “improved 




 When the two groups were compared, chemotherapy-related 
cutaneous reactions were seen more often in the group receiving the 
combination of clofarabine plus cytarabine (55% [22/40 patients]) 
than in those receiving clofarabine alone (10% [1/10 patients]; 
p=0.014). Of note, all four patients who developed erythroderma 
received the clofarabine and cytarabine combination regimen.  In 
addition (not included in the table), one patient developed leukemia 
cutis in the clofarabine alone group, and one patient developed 
petechiae due to thrombocytopenia in the combination group. The 
non-chemotherapy – related skin reactions include Morbilliform drug 
reaction to cephalosporin, Miliaria crystallina, and Sweet’s syndrome, 
and all of which occurred in the combination therapy group.  
 
All of the patients developed TEC between day 3 and day 9 post 
administration of chemotherapy, and all but one of the skin eruptions 
appeared within the first week of chemotherapy administration. The 
majority of skin symptoms were resolved within two to three weeks. In 
terms of location of the chemotherapy-related skin eruptions, hand 
and foot involvement were present in 16 out of 23 patients (70%), leg 
involvement were present in 6 patients (26%), arm involvement in 4 
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patients (17%), and abdomen and buttock involvement were found in 
2 patients (9%).  
 
Five patients in the study had received multiple cycles of the 
clofarabine only or the combination chemotherapy regimen, and one 
patient received one cycle of each regimen. All were separated by 
sufficiently long time intervals so they were considered separate 
exposures. Of note, one patient who received the combination regimen 
twice developed erythroderma in both incidences. Another patient who 
received the combination regimen twice developed palmar-plantar 
erythrodysesthesia during the first cycle, and developed miliaria 
crystallina during the second cycle. The rest of them did not develop 
chemotherapy-related skin toxicities despite multiple cycles of one 
regimen. Due to the small sample size, we could not make meaningful 
conclusions in regards to the correlation between number of cycles and 
the incidence of skin toxicity, nor could we conclude if prior skin 
toxicity would predict the same skin toxicity reaction during the second 
exposure. 
 
In terms of treatment for TEC that patients received in this 
series, the majority of them received oral pyridoxine 100mg TID, 
petroleum jelly based ointment, and one patient received Xeroform® 
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wound care for severe skin desquamation and blistering.  A few of the 





The development of toxic chemotherapy-related skin reactions in 
over half of the patients who received the combination of clofarabine 
plus cytarabine is clinically important (Table 2). In the series by Faderl 
et al.(120), where patients received the same regimen as in our series, 
two-thirds developed a cutaneous eruption that was described as 
either a non-specific skin rash or hand-foot syndrome, and when a 
similar regimen (but with a reduced dose of clofarabine [30mg/m2]) 
was utilized for reduced-intensity conditioning prior to allogeneic 
hematopoietic stem cell transplant, skin toxicity was observed in 56% 
of patients(123). In this latter group, approximately two-thirds of 
those with skin toxicities had hand-foot syndrome, with no specific 
descriptions for the remainder. Compared to clofarabine alone, there 
was statistically significant (p=0.014) enhanced cutaneous toxicity 
with the combination regimen in our series.  
 
Our report emphasizes the range of toxic reactions that can 
occur as a manifestation of TEC. While allergic drug reactions may 
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generalize and lead to erythroderma, it should be noted that an 
erythroderma due to severe TEC is toxic in nature and can be 
managed by dose reduction in the next treatment cycle. In addition, 
when bullae develop within the areas of diffuse erythema, the 
misdiagnosis of toxic epidermal necrolysis (TEN) may be rendered, as 
in the initial dermatology consult notes in one patient with grade IV 
erythroderma. Because of the overlap in the histologic features of TEN 
versus erythrodermic TEC with bullae, the distinction is based primarily 
on clinical findings, in particular the initial sites of involvement and the 
stability of the bullae. The life-threatening nature of severe TEC due to 
clofarabine plus cytarabine was highlighted by a recent case report 
(121) as well as our patient depicted in Figure 2. The onset of TEC is 
typically within 2 days to 3 weeks after the chemotherapy 
administration,(4) and in our series, the onset for almost all the 
patients was within the first week, which warrants attention of the 
clinicians to monitor closely the skin changes during the first week of 
the administration of clofarabine with or without cytarabine.  
 
Although there are reports and opinions that oral pyridoxine may 
prevent or lead to improvement of palmar-plantar 
erythrodysesthesia,(85) recent randomized, double-blind trials of oral 
pyridoxine versus placebo found no significant effect on the prevention 
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of hand-foot syndrome.(86, 87) Supportive care is essential for 
patients who have developed TEC and when it is severe, ICU-level care 
is often required. Treatment measures include pain control and placing 
windows in the most dependent portions of bullae in order to allow 
drainage of initially sterile fluid while preserving the blister roof as a 
“natural bandage”. Recognizing the toxic nature of the cutaneous 
reaction, followed by dose reductions in the future, are key elements 
of patient care. 
 
There are several limitations of the study. First, it is a 
retrospective chart review study, therefore the descriptions and 
grading of skin toxicities are based on the chart descriptions, as 
oppose to real time observations. Second, the small sample size 
limited statistical significance of analyses including the implication of 
multiple cycles and previous exposures in correlation with skin 
eruptions. Third, the scope of the study is restricted to a specific 
regimen of clofarabine and cytarabine. Therefore a dose-response of 
the skin toxicity could not be studied.  
 
In conclusion, this retrospective study indicated that TEC, 
ranging from palmar-plantar erythrodysthesia, to erythema of major 
body folds to diffuse erythema, were more frequently observed in 
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patients receiving clofarabine (40mg/m2/d x 5 d) plus cytarabine 
(1g/m2/d for 5 d) compared to clofarabine at the same dose alone. 
The majority of cutaneous skin toxicities in this regimen is TEC, which 
typically occurs within the first week. Clinicians should be aware of the 
differential diagnosis of cutaneous toxicities and have a high suspicion 
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Figure 1: Distribution pattern for toxic erythema of 
chemotherapy (TEC). The number of sites involved varies but the 
distribution remains symmetrical. Areas of dusky erythema appear 
that may be associated with burning or pain as well as superimposed 
sterile bullae (represented in yellow). Reproduced from Parker TL, 
Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy 
following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone 




Figure 2: A schematic presentation of the spectrum of toxic 








Figure 3 A, B: Severe toxic erythema of chemotherapy (TEC) in 
a patient who received both clofarabine and cytarabine. In 
occasional patients, the erythema becomes generalized, leading to an 
erythroderma that resembles a severe sunburn (but without sparing of 
non-sun-exposed sites). The superimposed bullae are more stable 


















Table 1: Patient demographics, hematologic malignancies, and 
therapies. The mean age at time of treatment was 47 years (range, 
20-77 years).*1 patient treated with both regimens; †4 patients had 
unknown transplant history. 
 
 









Acute lymphoid leukemia 




Disease status (prior to treatment) 
Primary refractory 





































Table 2. Cutaneous reactions to the two chemotherapeutic 
regimens. *In addition, one patient developed leukemia cutis 
(clofarabine alone group) and one patient developed petechiae due to 
thrombocytopenia (clofarabine plus cytarabine group); ** Two 
patients developed bilateral non-infectious lower extremity erythema 





Chemotherapeutic regimen (No. of 
patients) 























• Sweet’s syndrome 0 1 



















CTCAE 4.3 grade  & definition 
Erythroderma Palmar-plantar 
erythrodysesthesia syndrome 
Grade  Definition Grade  Definition 
1 - 1 Minimal skin changes or 
dermatitis (e.g. 
erythema, edema, or 
hyperkeratosis) without 
pain 
2 Erythema covering >90% 
BSA without associated 
symptoms, limiting 
instrumental ADL 
2 Skin changes (e.g. 
peeling, blistering, 
bleeding, edema, or 
hyperkeratosis) with 
pain ; limiting 
instrumental ADL 
3 Erythema covering >90% 
BSA with associated 
symptoms (e.g. pruritus 
or tenderness); limiting 
self care ADL 




pain, limiting self care 
ADL 
4 Erythema covering >90% 
BSA with associated fluid 
or electrolyte 
abnormalities; ICU care 
or burn unit indicated  
4 - 
5 Death   - 
 
 
 
 
